leadf
logo-loader
viewBioPorto

BioPorto and University of Southern Denmark make progress on 10-minute coronavirus test

The company's Generic Rapid Assay Device helped achieve promising results with heat-inactivated coronavirus

Coronavirus graphic
In the coming months, BioPorto plans to perfect the test using different sample types from known-positive patients

BioPorto Diagnostics A/S (CPH:BIOPOR) said its fast-track collaboration with the University of Southern Denmark (SDU) to create a 10-minute test for the coronavirus (COVID-19) has yielded promising results in tests against heat-inactivated virus.

The collaboration, announced in April, leverages SDU’s antibody expertise and BioPorto’s Generic Rapid Assay Device (gRAD) platform for the development of lateral flow assays to develop a non-invasive rapid test for SARS-CoV-2, the virus that causes COVID-19. 

The SARS-CoV-2 antibodies are highly specific to the virus’s spike protein, which could result in a higher clinical specificity compared to other commercially available rapid tests.

READ: BioPorto sees revenue from its NGAL kidney test nearly double in second-quarter 2020

In the coming months, BioPorto plans to perfect the test using different sample types from known-positive patients. If successful, the company intends to request an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and to apply for a CE Mark in Europe, which could lead to a product launch before the end of the year.

“The expedited development of a gRAD-based COVID-19 test and our promising analytical results have been very encouraging,” CEO Peter Eriksen said in a statement. “In a short time, we have been able to develop a test and bring it to the clinical evaluation stage. If we achieve our goals, the new COVID test, for the detection of the active virus, will demonstrate the value of our gRAD platform for fast and flexible creation of lateral flow assays, but more importantly, it could help make a real difference in global efforts to slow the virus through broad-based testing.”

Looking ahead, BioPorto maintained its financial guidance for 2020, projecting full-year revenue of approximately DKK 30 million (US$4.8 million). The company expects an operating loss of approximately DKK 73 million (US$11.7 million).

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

BioPorto maintains sales momentum of NGAL test, begins patient enrollment...

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive in its third quarter, NGAL Test revenue was up 17% compared to the same quarter last year, proving that revenue from the test has not been affected by delays caused by the coronavirus pandemic. Eriksen says what's more,...

2 weeks, 1 day ago

2 min read